AAPL327.36+0.77 (+0.23%) ▲|ABBV255.33+1.95 (+0.77%) ▲|ABT100.05-1.61 (-1.58%) ▼|ACN140.89-3.84 (-2.65%) ▼|ADBE226.71-8.03 (-3.42%) ▼|AMAT567.75+42.05 (+8.00%) ▲|AMD541.70+38.13 (+7.57%) ▲|AMGN364.49+0.32 (+0.09%) ▲|AMT163.75-3.32 (-1.98%) ▼|AMZN248.49-1.51 (-0.60%) ▼|AVGO386.17+8.01 (+2.12%) ▲|AXP351.03-0.90 (-0.26%) ▼|BA204.31-5.18 (-2.47%) ▼|BAC61.30+0.88 (+1.45%) ▲|BKNG177.97-1.48 (-0.82%) ▼|BLK1,040.96-13.15 (-1.25%) ▼|BMY60.47+0.31 (+0.51%) ▲|BNY158.67+1.74 (+1.11%) ▲|BRK-B489.69-1.56 (-0.32%) ▼|C132.90+4.18 (+3.25%) ▲|CAT889.71+25.41 (+2.94%) ▲|CL90.08-1.86 (-2.02%) ▼|CMCSA23.78-0.01 (-0.02%) ▼|COF206.12-0.65 (-0.31%) ▼|COP117.06+1.38 (+1.19%) ▲|COST931.02-4.78 (-0.51%) ▼|CRM170.24-3.55 (-2.04%) ▼|CSCO111.37+0.67 (+0.61%) ▲|CVS109.60+1.99 (+1.85%) ▲|CVX189.98+0.27 (+0.14%) ▲|DE589.47+3.47 (+0.59%) ▲|DHR178.69-22.42 (-11.15%) ▼|DIS96.50+0.09 (+0.09%) ▲|DUK125.59-0.26 (-0.21%) ▼|EMR139.43+2.85 (+2.09%) ▲|FDX314.80+8.58 (+2.80%) ▲|GD369.90-0.70 (-0.19%) ▼|GE340.98-0.33 (-0.10%) ▼|GEV1,083.23+4.05 (+0.38%) ▲|GILD129.80-3.41 (-2.56%) ▼|GM79.64+3.84 (+5.07%) ▲|GOOG348.19-3.18 (-0.91%) ▼|GOOGL348.89-3.10 (-0.88%) ▼|GS1,082.40+27.37 (+2.59%) ▲|HD330.63-2.41 (-0.72%) ▼|HON230.23+4.05 (+1.79%) ▲|IBM211.29-1.71 (-0.80%) ▼|INTC105.07+8.01 (+8.25%) ▲|INTU290.07-3.76 (-1.28%) ▼|ISRG357.26+4.09 (+1.16%) ▲|JNJ249.27+0.45 (+0.18%) ▲|JPM344.88+6.01 (+1.77%) ▲|KO82.09-0.04 (-0.04%) ▼|LIN506.73-5.32 (-1.04%) ▼|LLY1,163.31+16.41 (+1.43%) ▲|LMT505.40-4.14 (-0.81%) ▼|LOW203.42-1.29 (-0.63%) ▼|LRCX320.97+14.21 (+4.63%) ▲|MA538.78-8.66 (-1.58%) ▼|MCD265.19-2.45 (-0.92%) ▼|MDLZ59.79-0.49 (-0.80%) ▼|MDT82.31-0.98 (-1.18%) ▼|META647.02+1.17 (+0.18%) ▲|MMM169.90+10.79 (+6.78%) ▲|MO73.31-1.36 (-1.81%) ▼|MRK125.69+1.29 (+1.04%) ▲|MS215.36+4.42 (+2.10%) ▲|MSFT398.61-3.68 (-0.91%) ▼|MU974.66+109.20 (+12.62%) ▲|NEE87.92-0.08 (-0.09%) ▼|NFLX67.46-0.15 (-0.21%) ▼|NKE43.11-0.37 (-0.84%) ▼|NOW101.47-3.24 (-3.09%) ▼|NVDA206.09+2.81 (+1.38%) ▲|ORCL126.60+5.22 (+4.30%) ▲|PEP134.75-0.71 (-0.52%) ▼|PFE24.86+0.11 (+0.42%) ▲|PG147.65-1.49 (-1.00%) ▼|PLTR132.86-1.99 (-1.48%) ▼|PM189.68-3.04 (-1.58%) ▼|QCOM172.97+2.65 (+1.55%) ▲|RTX194.98+0.54 (+0.28%) ▲|SBUX104.48-0.33 (-0.31%) ▼|SCHW100.69-1.85 (-1.80%) ▼|SO93.68-0.78 (-0.83%) ▼|SPG226.54-1.65 (-0.72%) ▼|T22.09+0.14 (+0.62%) ▲|TMO523.98-2.25 (-0.43%) ▼|TMUS191.72-3.92 (-2.00%) ▼|TSLA380.14+10.57 (+2.86%) ▲|TXN293.49+9.42 (+3.32%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH434.26+12.71 (+3.02%) ▲|UNP294.41-1.85 (-0.62%) ▼|UPS115.91+2.76 (+2.43%) ▲|USB63.35+0.21 (+0.32%) ▲|V356.82-3.76 (-1.04%) ▼|VZ43.47-0.03 (-0.07%) ▼|WFC87.96+1.63 (+1.89%) ▲|WMT110.46-1.74 (-1.55%) ▼|XOM150.90+2.54 (+1.71%) ▲|AAPL327.36+0.77 (+0.23%) ▲|ABBV255.33+1.95 (+0.77%) ▲|ABT100.05-1.61 (-1.58%) ▼|ACN140.89-3.84 (-2.65%) ▼|ADBE226.71-8.03 (-3.42%) ▼|AMAT567.75+42.05 (+8.00%) ▲|AMD541.70+38.13 (+7.57%) ▲|AMGN364.49+0.32 (+0.09%) ▲|AMT163.75-3.32 (-1.98%) ▼|AMZN248.49-1.51 (-0.60%) ▼|AVGO386.17+8.01 (+2.12%) ▲|AXP351.03-0.90 (-0.26%) ▼|BA204.31-5.18 (-2.47%) ▼|BAC61.30+0.88 (+1.45%) ▲|BKNG177.97-1.48 (-0.82%) ▼|BLK1,040.96-13.15 (-1.25%) ▼|BMY60.47+0.31 (+0.51%) ▲|BNY158.67+1.74 (+1.11%) ▲|BRK-B489.69-1.56 (-0.32%) ▼|C132.90+4.18 (+3.25%) ▲|CAT889.71+25.41 (+2.94%) ▲|CL90.08-1.86 (-2.02%) ▼|CMCSA23.78-0.01 (-0.02%) ▼|COF206.12-0.65 (-0.31%) ▼|COP117.06+1.38 (+1.19%) ▲|COST931.02-4.78 (-0.51%) ▼|CRM170.24-3.55 (-2.04%) ▼|CSCO111.37+0.67 (+0.61%) ▲|CVS109.60+1.99 (+1.85%) ▲|CVX189.98+0.27 (+0.14%) ▲|DE589.47+3.47 (+0.59%) ▲|DHR178.69-22.42 (-11.15%) ▼|DIS96.50+0.09 (+0.09%) ▲|DUK125.59-0.26 (-0.21%) ▼|EMR139.43+2.85 (+2.09%) ▲|FDX314.80+8.58 (+2.80%) ▲|GD369.90-0.70 (-0.19%) ▼|GE340.98-0.33 (-0.10%) ▼|GEV1,083.23+4.05 (+0.38%) ▲|GILD129.80-3.41 (-2.56%) ▼|GM79.64+3.84 (+5.07%) ▲|GOOG348.19-3.18 (-0.91%) ▼|GOOGL348.89-3.10 (-0.88%) ▼|GS1,082.40+27.37 (+2.59%) ▲|HD330.63-2.41 (-0.72%) ▼|HON230.23+4.05 (+1.79%) ▲|IBM211.29-1.71 (-0.80%) ▼|INTC105.07+8.01 (+8.25%) ▲|INTU290.07-3.76 (-1.28%) ▼|ISRG357.26+4.09 (+1.16%) ▲|JNJ249.27+0.45 (+0.18%) ▲|JPM344.88+6.01 (+1.77%) ▲|KO82.09-0.04 (-0.04%) ▼|LIN506.73-5.32 (-1.04%) ▼|LLY1,163.31+16.41 (+1.43%) ▲|LMT505.40-4.14 (-0.81%) ▼|LOW203.42-1.29 (-0.63%) ▼|LRCX320.97+14.21 (+4.63%) ▲|MA538.78-8.66 (-1.58%) ▼|MCD265.19-2.45 (-0.92%) ▼|MDLZ59.79-0.49 (-0.80%) ▼|MDT82.31-0.98 (-1.18%) ▼|META647.02+1.17 (+0.18%) ▲|MMM169.90+10.79 (+6.78%) ▲|MO73.31-1.36 (-1.81%) ▼|MRK125.69+1.29 (+1.04%) ▲|MS215.36+4.42 (+2.10%) ▲|MSFT398.61-3.68 (-0.91%) ▼|MU974.66+109.20 (+12.62%) ▲|NEE87.92-0.08 (-0.09%) ▼|NFLX67.46-0.15 (-0.21%) ▼|NKE43.11-0.37 (-0.84%) ▼|NOW101.47-3.24 (-3.09%) ▼|NVDA206.09+2.81 (+1.38%) ▲|ORCL126.60+5.22 (+4.30%) ▲|PEP134.75-0.71 (-0.52%) ▼|PFE24.86+0.11 (+0.42%) ▲|PG147.65-1.49 (-1.00%) ▼|PLTR132.86-1.99 (-1.48%) ▼|PM189.68-3.04 (-1.58%) ▼|QCOM172.97+2.65 (+1.55%) ▲|RTX194.98+0.54 (+0.28%) ▲|SBUX104.48-0.33 (-0.31%) ▼|SCHW100.69-1.85 (-1.80%) ▼|SO93.68-0.78 (-0.83%) ▼|SPG226.54-1.65 (-0.72%) ▼|T22.09+0.14 (+0.62%) ▲|TMO523.98-2.25 (-0.43%) ▼|TMUS191.72-3.92 (-2.00%) ▼|TSLA380.14+10.57 (+2.86%) ▲|TXN293.49+9.42 (+3.32%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH434.26+12.71 (+3.02%) ▲|UNP294.41-1.85 (-0.62%) ▼|UPS115.91+2.76 (+2.43%) ▲|USB63.35+0.21 (+0.32%) ▲|V356.82-3.76 (-1.04%) ▼|VZ43.47-0.03 (-0.07%) ▼|WFC87.96+1.63 (+1.89%) ▲|WMT110.46-1.74 (-1.55%) ▼|XOM150.90+2.54 (+1.71%) ▲|
27.4 C
New York
Tuesday, July 21, 2026

Tag: patient information

newssourceFORcompanyinformationcontent1releasesmarket

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

FDA Approves Labeled Strength Update of TWIRLA® (levonorgestrel/ethinyl estradiol) Birth Control Patch

FLORHAM PARK, N.J., June 19, 2026 (GLOBE NEWSWIRE) -- Exeltis USA, Inc. (Exeltis), a global pharmaceutical company specializing in women’s health, announced that the U.S. Food and Drug Administration (FDA) has approved an update to the labeled strength of TWIRLA® (levonorgestrel and ethinyl estradiol) transdermal system. The new labeled strength will begin to appear on the market in September or October of 2026.

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

M2M Healthcare Market Size to Reach USD 28.77 Billion by 2031 Driven by Connected Healthcare and Remote Monitoring Adoption | Valuates Reports

BANGALORE, India, June 10, 2026 /PRNewswire/ -- ...

M2M Healthcare Market Size to Reach USD 28.77 Billion by 2031 Driven by Connected Healthcare and Remote Monitoring Adoption | Valuates Reports

BANGALORE, India, June 10, 2026 /PRNewswire/ -- ...

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources 
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

BrightSpring Health Services, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

LOUISVILLE, Ky., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the second quarter ended June 30, 2025, and increased Revenue and Adjusted EBITDA1 guidance.

Happy Docs Make Happy Patients

AI technology boosts face-to-face time with patients, earns Mercy national recognition for physician satisfaction ST. LOUIS, July 23, 2025 /PRNewswire/ -- Mercy's strategic and carefully planned...

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient information

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers